124480-95-1

Usage

Uses

Used in Pharmaceutical Research:
3,5-DIETHOXYBENZOIC ACID is used as a building block for the synthesis of various pharmaceuticals and bioactive compounds, leveraging its unique chemical structure to contribute to the development of new drugs.
Used in Organic Synthesis:
3,5-DIETHOXYBENZOIC ACID is utilized as a key intermediate in organic synthesis, enabling the creation of a range of chemical products through its versatile reactivity.
Used in Antifungal Applications:
3,5-DIETHOXYBENZOIC ACID is used as an antifungal agent, harnessing its potential biological activity to combat fungal infections.
Used in Antibacterial Applications:
3,5-DIETHOXYBENZOIC ACID is employed as an antibacterial agent, leveraging its properties to inhibit bacterial growth, thereby contributing to the development of new antimicrobial treatments.

InChI:InChI=1/C11H14O4/c1-3-14-9-5-8(11(12)13)6-10(7-9)15-4-2/h5-7H,3-4H2,1-2H3,(H,12,13)

Upstream product

• 198623-55-1 3,5-diethoxybenzoic acid methyl ester 
• 4142-98-7 ethyl 3,5-dihydroxybenzoate 
• 351002-95-4 3,5-diethoxybenzoic acid ethyl ester 

Downstream Products

• 198623-55-1 3,5-diethoxybenzoic acid methyl ester 
• 1282544-01-7 2-{[(3,5-diethoxybenzoyl)(3-phenylpropyl)amino]methyl}-N-[(dimethylamino)sulfonyl]-1,3-thiazole-4-carboxamide 
• 124-38-9 carbon dioxide 
• 2049-73-2 2,4-diethoxybenzene 

Relevant academic research and scientific papers

Aspartyl protease inhibitors

The present invention provides compounds having the formula: wherein R1, R′, R2, R3, R3′, R4, X1, X2 and X3 are as defined herein, and pharmaceutical compositions thereof. The present invention also provides methods of inhibiting proteases, more specifically aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer's Disease). The present invention also provides methods for preparing compounds of the invention.

ASPARTYL PROTEASE INHIBITORS

The present invention provides compounds having formula (I): wherein R’, R0, R1, X1, R2, R3, R3’, X2, X3, and R4 are as defined herein, and pharmaceuticals compositions thereof. The present invention also provides methods of inhibiting proteases, more specially aspartyl proteases. In certain embodiments, compounds inhibit BACE (β-site APP-cleaving enzyme), and thus are useful in the treatment or prevention of a disease characterized by β-amyloid deposits in the brain (including, but not limited to, Alzheimer’s Disease). The present invention also provides methods for preparing compounds of the invention.